Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 7 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 10465194

    Complement component iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted

  2. US 10407679

    Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted

  3. US 10400239

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted

  4. US 10400238

    Polynucleotide agents targeting complement component C5 and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted

  5. US 10369226

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted

  6. US 10370666

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted

  7. US 10337010

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted

  8. US 10273477

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  9. US 10266484

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  10. US 10246713

    TMPRSS6 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted

  11. US 10246708

    Dosages and methods for delivering lipid formulated nucleic acid molecules

    Alnylam Pharmaceuticals, Inc. · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted

  12. US 10240152

    Compositions and methods for inhibiting expression of transthyretin

    Alnylam Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  13. US 10238749

    Angiotensinogen (AGT) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  14. US 10233448

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  15. US 10231988

    Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  16. US 10233452

    Compositions and methods for increasing erythropoietin (EPO) production

    Alnylam Pharmaceuticals, Inc. · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  17. US 10208307

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Alnylam Pharmaceuticals, Inc. · Granted Feb 19, 2019 · Expires Feb 14, 2039

    granted

  18. US 10195291

    Compositions and methods for the manufacture of lipid nanoparticles

    Alnylam Pharmaceuticals, Inc. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted

  19. US 10190118

    Methods and compositions for treating insects

    Alnylam Pharmaceuticals, Inc. · Granted Jan 29, 2019 · Expires Jan 24, 2039

    granted

  20. US 10131907

    Glycoconjugates of RNA interference agents

    Alnylam Pharmaceuticals, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted

  21. US 10125369

    PCSK9 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted

  22. US 10119143

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted

  23. US 10100312

    Compositions and methods for inhibiting expression of TMPRSS6 gene

    Alnylam Pharmaceuticals, Inc. · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted

  24. US 10086081

    Carbohydrate conjugated RNA agents and process for their preparation

    Alnylam Pharmaceuticals, Inc. · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.